$96.47
6.07%
Nasdaq, Sep 18, 04:03 pm EDT. Closed.
ISIN
US61023L1089
Symbol
MNPR

Monopar Therapeutics Inc Stock price

$96.47
-22.58 18.97% 1M
+38.17 65.47% 6M
+31.17 47.73% YTD
+30.22 45.62% 1Y
+93.51 3,159.12% 3Y
+71.17 281.30% 5Y
-36.03 27.19% 10Y
-36.03 27.19% 20Y
Nasdaq, Closing price Fri, Sep 18 2026
-6.23 6.07%
ISIN
US61023L1089
Symbol
MNPR
Industry

Is Monopar Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.

Key metrics

Basic
Market capitalization
$647.5m
Enterprise Value
$513.2m
Net debt
positive
Cash
$134.3m
Shares outstanding
6.7m
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
5.0
Financial Health
Equity Ratio
98.0%
Return on Equity
-10.0%
ROCE
-16.9%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
-
EBIT
$-22.1m
Net Income
$-17.8m
Free Cash Flow
$-12.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-
EBIT
-15.8%
Net Income
-3.1%
Free Cash Flow
-24.2%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
$-2.1
FCF per Share
$-1.8
Short interest
18.6%
Employees
22
Rev per Employee
$0.0

Monopar Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Monopar Therapeutics Inc forecast:

17x Buy
89%
2x Hold
11%

Analyst Opinions

19 Analysts have issued a Monopar Therapeutics Inc forecast:

Buy
89%
Hold
11%

Financial data from Monopar Therapeutics Inc

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 7.33 7.33
52% 52%
-
- Research and Development Expense 15 15
4% 4%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -22 -22
16% 16%
-
Net Profit -18 -18
3% 3%
-

In millions USD.

Don't miss a Thing! We will send you all news about Monopar Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Monopar Therapeutics Inc Stock News

Neutral
GlobeNewsWire
about one month ago
WILMETTE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Jeffrey D. Kent, M.D., FACP, FACG, as Executive Vice President, Head of Medical Affairs, effective September 1, 2026. The Comp...
Neutral
GlobeNewsWire
about one month ago
WILMETTE, Ill., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced second quarter 2026 financial results and provided business updates.
Neutral
GlobeNewsWire
about 2 months ago
WILMETTE, Ill., July 22, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that it has initiated the rolling submission of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for ALXN1840 (tio...
More Monopar Therapeutics Inc News

Company Profile

Monopar Therapeutics, Inc. is a a clinical stage biopharmaceutical company, which engages in building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages. Its product pipeline include Validive, Camsirubicin, and MNPR-101. The company was founded by Chandler D. Robinson, Christopher M. Starr, and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.

Head office United States
CEO Dr. Robinson
Employees 22
Founded 2014
Website www.monopartx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today